FDA Approves Jaypirca (Pirtobrutinib) for Two Rare Blood Cancers by Madaline Spencer| Published on: Oct 13, 2026

https://checkrare.com/fda-approves-jaypirca-pirtobrutinib-for-two-rare-blood-cancers/ The US Food and Drug Administration (FDA) has approved pirtobrutinib for adults with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) with no known 17p deletion. CLL/SLL are rare cancers that affect B lymphocytes. The conditions are similar in pathophysiology but differ primarily in location of the disease. In patients with CLL, the cancer mainly manifests in the bloodstream, while in patients with SLL, it is in the lymph nodes and lymphoid tissue. CLL accounts for the majority (90%) of cases. Early signs and symptoms may include swollen lymph nodes, fatigue, weight loss, fever, night sweats and/or frequent...